Singapore markets closed

Straits Times Index
3,313.48
+8.49(+0.26%)
Nikkei
38,787.38
-132.88(-0.34%)
Hang Seng
19,553.61
+177.08(+0.91%)
FTSE 100
8,420.26
-18.39(-0.22%)
Bitcoin USD
66,917.93
+1,391.27(+2.12%)
CMC Crypto 200
1,369.64
-4.20(-0.31%)

GILD Jan 2025 57.500 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

1.5400

-0.0600

(-3.75%)

As of 03:59PM EDT. Market open.

Loading interactive chart…

Business Wire
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
SANTA MONICA, Calif., May 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced 12 abstracts from its industry-leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology Association (EHA) Annual Congress, June 13-16, Madrid, Spain.
Yahoo Finance
One stock is dragging down the S&P 500's earnings growth
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
Zacks
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.